TG Therapeutics, Inc. (MHA) Provides Update On A Modified TGR-1202 Formulation And Fed-State Dosing With Data Demonstrating Significantly Higher TGR-1202 Exposure
5/8/2014 10:13:20 AM
NEW YORK, May 8, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company, today announced that a micronized (reduced particle size) formulation for the Company's novel, once-daily PI3K-delta inhibitor, TGR-1202, has demonstrated improved pharmacokinetics with approximately double the TGR-1202 exposure (AUC) in a healthy subject bioequivalence study. A second food-effect study in healthy subjects which evaluated the relative oral bioavailability and pharmacokinetics of TGR-1202 in a fed and fasted-state also demonstrated an approximate doubling in absorption with fed-state dosing. Together, the Company believes that these modifications may result in an approximately 3-4 fold increase in exposure over that seen in the ongoing Phase 1 study. Results from these studies will be included in a presentation of updated data from the ongoing Phase 1 study of TGR-1202 in patients with relapsed and refractory hematologic malignancies at the American Society of Clinical Oncology Meeting (ASCO) later this month.
Help employers find you! Check out all the jobs and post your resume.
comments powered by